Alemtuzumab in renal transplantation. Reviews of literature and usage in the United Kingdom
Author:
Funder
Novartis
Sanofi
Publisher
Elsevier BV
Subject
Transplantation
Reference95 articles.
1. Long-term allograft survival after kidney transplantation;Gómez;Transplant Proc,2013
2. Immunosuppression for kidney transplantation: where are we now and where are we going?;Lim;Transplant Rev,2017
3. Long-term renal allograft survival: a quiet revolution;Jardine;Kidney Int,2018
4. Long-term kidney transplant graft survival—making progress when most needed;Poggio;Am J Transplant,2021
5. Comparison of the long-term outcomes of kidney transplantation: USA versus Spain;Ojo;Nephrol Dial Transplant,2013
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Sequential administration of anti-complement component C5 eculizumab and type-2 anti-CD20 obinutuzumab for the treatment of early antibody-mediated rejection after kidney transplantation: A proof of concept;Clinical Immunology;2024-07
2. CPT-11 mitigates autoimmune diseases by suppressing effector T cells without affecting long-term anti-tumor immunity;Cell Death Discovery;2024-05-04
3. Long‐term outcomes of two‐dose alemtuzumab induction in pediatric kidney transplantation;Pediatric Transplantation;2024-04-16
4. Preoperative CD52 Level Predicts Graft Survival following Kidney Transplantation;BioMed Research International;2022-09-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3